Bionor Holding AS

📍 Oslo, Norway🗓 Founded 1986👥 7 employees💰 Last funded May 2015
Biotechnology🌐 bionorholding.com
Website LinkedIn
Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x and Vacc-C5 in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor retains full ownership rights to the HIV immunotherapy Vacc-4x and Vacc-C5, i.e., the upside potential from partnering or licensing remains with the Company.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
1986
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Norway
1
Denmark
1
Frequently asked questions
Who invested in Bionor Holding AS?
Bionor Holding AS has 2 investors on record on gritt.io.
When did Bionor Holding AS last raise funding?
The most recent investment in Bionor Holding AS recorded on gritt.io was in May 2015.
When was Bionor Holding AS founded?
Bionor Holding AS was founded in 1986.
What industry is Bionor Holding AS in?
Bionor Holding AS operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Bionor Holding AS based?
Bionor Holding AS is headquartered in Oslo, Norway.